ArticleMicroorganisms2023
Rapid Identification of Nontuberculous Mycobacterium Species from Respiratory Specimens Using Nucleotide MALDI-TOF MS.
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Diagnostic performance of nucleic acid MALDI-TOF MS in mycobacterial detection, species identification, and drug resistance testing for Mycobacterium tuberculosis.BMC infectious diseases · 2026Article
- Detection ofMicroorganisms · 2026Article
- Advanced diagnostic methods for nontuberculous mycobacterial infections.Frontiers in tuberculosis · 2026Review
- Rapid Triage of Smear-Positive Tuberculosis Suspects with a Commercial DNA Microarray: A Real-World Experience from 1100 Sputum Specimens.Infection and drug resistance · 2026Article
- Detection, Isolation, and Identification of Mycobacteria That Cause Nontuberculous Mycobacterial Disease and Tuberculosis.Pathogens (Basel, Switzerland) · 2025Review
- Diagnostic Performance of Nucleotide MALDI-TOF-MS for the Rapid Diagnosis of Pulmonary Tuberculosis and the Detection of Drug Resistance.Infection and drug resistance · 2025Article
- A comparative study using Xpert MTB/RIF and culture methods evaluates MassARRAY technology for rapid detection ofFrontiers in cellular and infection microbiology · 2025Article
- The Advance and Clinical Practice on Lung Disease Caused byInfection and drug resistance · 2025Article
- Evaluation of a Commercial Multiplex Real-Time PCR with Melting Curve Analysis for the Detection ofMicroorganisms · 2024Article
- Incorporating direct molecular diagnostics in management algorithms for nontuberculous mycobacteria: Is it high time?IJID regions · 2024Review
- Analysis of Clinical Isolation Characteristics of Nontuberculous Mycobacteria and Drug Sensitivity of Rapidly Growing Mycobacteria in the General Hospital of Guangzhou, China.Infection and drug resistance · 2024Article
- Identification of a Novel Nucleic Acid Target for the Rapid and Specific Detection ofAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We performed a prospective study to evaluate the diagnostic accuracy of nucleotide matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in identifying nontuberculous mycobacterium (NTM) from clinical respiratory samples. A total of 175 eligible patients were prospectively enrolled, including 108 patients diagnosed with NTM pulmonary disease (NTM-PD) and 67 control patients with other diseases. All specimens were subjected to acid-fast staining, liquid culture combined with MPT64 antigen detection, and a nucleotide MALDI-TOF MS assay. NTM cultures were also subjected to the MeltPro Myco assay for species identification. Altogether, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of nucleotide MALDI-TOF MS were 77.8% (95% CI: 68.6-85.0%), 92.5% (82.8-97.2%), 94.4% (86.8-97.9%), and 72.1% (61.2-81.0%), respectively; these results were not statistically different from the results of culture + MPT64 antigen testing (75.0% [65.6-82.6%], 95.5% [86.6-98.8%], 96.4% [89.2-99.1%], and 70.3% [59.7-79.2%], respectively). In the identification of NTM species, of the 84 nucleotide MALDI-TOF MS positive samples, 77 samples (91.7%) were identified at the species level. Using culture + MeltPro Myco assay as the reference standard, nucleotide MALDI-TOF MS correctly identified 77.8% (63/81) of NTM species. Our results demonstrated that the nucleotide MALDI-TOF MS assay was a rapid single-step method that provided the reliable detection of NTM and identification of NTM species. This new method had the same sensitivity and specificity as the culture + MPT64 antigen method, but was much more rapid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.